Brand Reference: Actigall, Urso Forte
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ursodiol (Ursodeoxycholic Acid / UDCA) RxNorm Concept ID | 11065 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $158.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $18.40 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $22.00 / mo | 18 Zero-PHI Verified Patient Logs |
Replaces hydrophobic cytotoxic bile acids inside the enterohepatic pool, suppresses hepatic HMG-CoA biliary cholesterol saturation, and prevents rapid-weight-loss cholelithiasis (gallstones) during aggressive >1.5 kg/week GLP-1 or bariatric weight reduction.
CMS National Average Drug Acquisition Cost (NADAC) tracking places Ursodiol (Ursodeoxycholic Acid / UDCA) (Actigall / Urso Forte, RxCUI 11065) at $0.5800 per unit, whereas walk-in chain pharmacies bill cash patients an average of $158.00 monthly—creating a 88% ($139.60/mo) wholesale arbitrage spread down to $18.40.
Systemic exposure to Ursodiol (Ursodeoxycholic Acid / UDCA) reflects 90% small-intestinal passive absorption absorption kinetics and hepatic glycine/taurine conjugation and colonic 7-dehydroxylation to fecal lithocholic acid, sustaining receptor engagement across a 3.5–5.8 days enterohepatic pool turnover half-life window (3–4 weeks bile desaturation response profile).
Dosing protocols (300 mg PO BID (600 mg/day rapid-weight-loss gallstone prophylaxis) or 13–15 mg/kg/day divided) balance efficacy (90.00% patient satisfaction across 18 logs) against soft stools / mild diarrhea (15% of reports), dyspepsia (6% of reports), with strict avoidance in calcified radio-opaque gallstones; acute biliary tract obstruction or cholecystitis.
Across 18 verified cash-pay logs, Ursodiol (Ursodeoxycholic Acid / UDCA) achieves a 90.00% Worth-It rating with out-of-pocket spend averaging $22.00/mo versus $158.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 300 mg PO BID (600 mg/day rapid-weight-loss gallstone prophylaxis) for Ursodiol (Ursodeoxycholic Acid / UDCA); monthly out-of-pocket dropped to $16.19 compared with $158.00 retail.
Completed 10 weeks on Ursodiol (Ursodeoxycholic Acid / UDCA) (13–15 mg/kg/day divided). Zero notable side effects on steady dosing.
Consistent biomarker response on 300 mg PO BID (600 mg/day rapid-weight-loss gallstone prophylaxis) Ursodiol (Ursodeoxycholic Acid / UDCA) sourced via Cost Plus Drugs ($21.34/mo cash pay without insurance prior authorization).